7 active not recruiting. 7 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Active not recruiting 7 |
| Phase 2 | 2 | Active not recruiting 2 |
Follow Large B-cell Lymphoma: new trials by email Literature Review of Large B-cell Lymphoma trials Research Report on Large B-cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID) SC262 - Non Hodgkin's Lymphoma, Large B-cell Lymphoma | Phase 1 | Active not recruiting | Sana Biotechnology | 6 | 2024-04-18 | 2025-11-28 |
| Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies SYNCAR-001, STK-009, Cyclophosphamide - CLL/SLL, NHL | Phase 1 | Active not recruiting | Synthekine | 36 | 2023-04-23 | 2026-07-10 |
| Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma 19(T2)28z1xx TRAC T cell - B-Cell Lymphoma, Large B-cell Lymphoma | Phase 1 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 30 | 2023-02-23 | 2026-04-22 |
| Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma Mosunetuzumab, DHAX, ICE - Large B-cell Lymphoma, High-grade B-cell Lymphoma | Phase 1 | Active not recruiting | Washington University School of Medicine | 24 | 2023-01-03 | 2026-01-08 |
| Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma CD19-targeted chimeric antigen receptor T-cell - Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Pell Bio-Med Technology Co., Ltd. | 49 | 2022-05-31 | 2026-10-09 |
| NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers NKX019 - Lymphoma, Non-Hodgkin, B-cell Acute Lymphoblastic Leukemia | Phase 1 | Active not recruiting | Nkarta, Inc. | 150 | 2021-08-20 | 2026-04-20 |
| Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL Rapcabtagene autoleucel single agent, Ibrutinib - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 217 | 2019-06-26 | 2026-06-04 |
Lymphoma, Large B-Cell, Diffuse (4) · Lymphoma, Mantle-Cell (3) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma, Follicular (2) · Lymphoma, Non-Hodgkin (2) · Burkitt Lymphoma (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Lymphoma, B-Cell (1) · Lymphoma, B-Cell, Marginal Zone (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Waldenstrom Macroglobulinemia (1)
Hemic and Lymphatic Diseases (6) · Immune System Diseases (6) · Immunoproliferative Disorders (6) · Lymphatic Diseases (6) · Lymphoma (6) · Lymphoproliferative Disorders (6) · Neoplasms (6) · Neoplasms by Histologic Type (6) · Lymphoma, B-Cell (5) · Lymphoma, Non-Hodgkin (4) · Chronic Disease (2) · Disease Attributes (2) · Hematologic Diseases (2) · Leukemia (2) · Leukemia, B-Cell (2)
Cyclophosphamide (2) · fludarabine (2) · Ice (1) · ibrutinib (1)
Memorial Sloan Kettering Cancer Center (1) · Nkarta, Inc. (1) · Novartis Pharmaceuticals (1) · Pell Bio-Med Technology Co., Ltd. (1) · Sana Biotechnology (1) · Synthekine (1) · Washington University School of Medicine (1)
United States (6) · Australia (2) · Austria (1) · France (1) · Germany (1) · Italy (1) · Japan (1) · Spain (1) · Taiwan (1)
Chen-Lung Lin, MD (1) · David Russler-Germain, M.D., Ph.D. (1) · David Shook, MD (1) · Jae Park, MD (1) · John Gerecitano, MD, PhD (1)